Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis
Open Access
- 30 March 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (5), 907-913
- https://doi.org/10.3899/jrheum.080592
Abstract
Objective.Patients with rheumatoid arthritis (RA) commonly switch between tumor necrosis factor (TNF) inhibitors after failing to control disease activity. Much of the clinical data that support switching to a second TNF agent when one agent fails to work has come from small, short-term studies. We utilized a US insurance claims database to determine patterns of use such as dose escalation, time to discontinuation, and switching between TNF inhibitors in patients with RA.Methods.A retrospective analysis was performed using an insurance claims database in the US from 2000 to 2005. TNF inhibitor use, time to switch, dose escalation, and continuation times were analyzed in patients with RA.Results.Nine thousand seventy-four patients with RA started TNF inhibitors during the period 2000 to 2005. Etanercept was the most commonly used TNF inhibitor; infliximab had the highest duration of continuation, about 50% at 2 years. In addition, infliximab showed higher rates of dose escalation compared to etanercept and adalimumab. For all TNF inhibitors, time to switching decreased from 2000 to 2005.Conclusion.TNF inhibitor use patterns changed from 2000 to 2005, with more frequent changes among the different TNF inhibitors and a shorter duration of treatment before the change. Only about 50% of TNF inhibitors are still continued at 2 years, reflecting the difference between randomized clinical trials and real-world experience.This publication has 15 references indexed in Scilit:
- Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort studyArthritis & Rheumatism, 2007
- Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologistsJoint Bone Spine, 2006
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisThe New England Journal of Medicine, 2006
- Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effectsAnnals Of The Rheumatic Diseases, 2006
- Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled studyAnnals Of The Rheumatic Diseases, 2006
- Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Research & Therapy, 2006
- Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University HospitalScandinavian Journal of Rheumatology, 2005
- Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?Annals Of The Rheumatic Diseases, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make senseAnnals Of The Rheumatic Diseases, 2003
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002